Clinical Trial

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-07-21
notable Trial sites expanded: 25 -> 28 locations 2026-07-21
notable Primary completion pushed: 2026-09 -> 2027-05 2026-07-21
minor Completion pushed: 2026-09 -> 2027-06 2026-07-21
Trial Details
NCT Number NCT05320198
Lead Sponsor Disc Medicine, Inc
Conditions Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Enrollment 150 participants
Start Date 2022-06-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-12